The EBITDA margin stood at 26% in the reporting quarter versus 23.1% YoY. The results came after the close of the market hours. Shares of Gland Pharma Ltd ended at ₹1,512.15, down by ₹16.55, or 1.08%, on the BSE.
The EBITDA margin stood at 26% in the reporting quarter versus 23.1% YoY. The results came after the close of the market hours. Shares of Gland Pharma Ltd ended at ₹1,512.15, down by ₹16.55, or 1.08%, on the BSE.